Roche links with Boehringer Ingelheim in companion Dx deal
Roche's Ventana Medical Systems division will link up with Germany's Boehringer Ingelheim to develop companion diagnostic tests for new cancer drugs. Neither side is disclosing financial details, but the deal is the latest example of how personalized medicine now routinely links the drug development and diagnostics worlds.
Exosome, Mount Sinai forge Dx development partnership
New York's Exosome Diagnostics will enlist Mount Sinai Medical Center's research expertise to concoct new molecular diagnostics focused on cancer, inflammation and other diseases that don't rely on tissue biopsies.
Are cancer biomarker tests grossly underused?
A cadre of researchers, academics, insurers and patient advocates are calling for major reform in how tumor biomarker tests are regulated, reimbursed and developed. They argue that the current system leaves the diagnostic tools chronically underused and holds back the advance of personalized cancer care.
Math models tailor drug delivery using patient DNA
Researchers from the U.S. and China have developed statistical models that simulate a drug's reaction in a patient, an innovation that could help deliver treatments to specific disease targets.
In hot biotech market, personalized drugs rise to the top
Investor interest in biotech is enjoying a prosperous comeback, leading industry watchers and journalists to seek reasons for the frenzy. In The New York Times ' DealBook post, one of the recurring themes among the high-flying drug developers, was a focus on personalized medicine.
UPDATED: In mixed decision, Supreme Court throws up a barrier around gene patents
In a mixed decision, the Supreme Court has ruled that companies can not obtain a patent on human genes. But companies like Myriad Genetics will be able to nail down patent protection on complementary gene work, or cDNA, which requires human tinkering.
Cenix to collaborate with Debiopharm on predictive biomarkers
The preclinical CRO Cenix BioScience has struck a deal to work with Germany's Debiopharm, putting its experts to work finding predictive biomarkers that can be used to advance the biotech's cancer drug candidates.
Biosensors International grabs next-gen imaging company for $51M
Swiss cardiac stent maker Biosensors International will pay at least $51 million for U.S.-based Spectrum Dynamics, a developer of high-definition medical imaging technology.
Bristol-Myers Squibb pursues cancer biomarker development deal
Bristol-Myers Squibb will collaborate with Adaptive Biotechnologies to develop immunological biomarkers for cancer, representing another step forward in the development of personalized medicine.
UPDATED: Biodesix snags $8.8M to boost lung cancer Dx commercial push
Biodesix reeled in another $8.8 million in financing toward expanding sales and marketing for VeriStrat, its molecular diagnostic blood test to help guide treatment for patients with advanced non-small cell lung cancer. The new funding will also propel further research work involving the technology.